Loh Huai Heng, Tay Siow Phing, Koa Ai Jiun, Yong Mei Ching, Said Asri, Chai Chee Shee, Malik Natasya Marliana Abdul, Su Anselm Ting, Tang Bonnie Bao Chee, Tan Florence Hui Sieng, Azizan Elena Aisha, Sukor Norlela
Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Sarawak, Malaysia.
Trop Med Health. 2025 Apr 27;53(1):62. doi: 10.1186/s41182-025-00742-4.
Hypertension commonly co-exists with obstructive sleep apnea (OSA). However, the role of renin-angiotensin-aldosterone system (RAAS) in the development of hypertension in OSA patients remains poorly defined, with inconclusive evidence regarding the activation of the RAAS in these patients. Herein, we aimed to evaluate the RAAS profile in OSA patients and to elucidate the influence of RAAS on hypertension in these individuals.
In this observational study, patients referred from health clinics aged 18 years and older, with obesity, defined as body mass index greater than 27.5 kg/m, and confirmed OSA were recruited if they met study criteria. Anthropometric data were collected, and blood sampled for plasma aldosterone concentration (PAC) and plasma renin concentration (PRC). Treatment intensity was assessed using the therapeutic intensity score (TIS). The RAAS components were compared between the OSA patients, healthy controls, and patients with confirmed primary aldosteronism.
A total of 204 patients who fulfilled the study criteria were recruited, of which 160 had hypertension. Patients with hypertensive OSA demonstrated higher PAC with no significant difference in PRC compared to normotensive OSA; and higher PAC and ARR with lower PRC compared to healthy controls. PAC was positively correlated with TIS (β = 0.281, p < 0.001), systolic blood pressure (β = 0.156, p = 0.049), and hypertension duration (β = 0.168, p = 0.011), while negatively correlated with hypertension diagnosis (β = - 0.170, p = 0.024).
This is the first study from Southeast Asia evaluating the impact of RAAS on hypertension severity in OSA patients. Findings suggest that hypertensive individuals with OSA exhibit greater RAAS dysregulation, highlighting the role of aldosterone in the development of hypertension and its severity in OSA. This also underscores the need for targeted management strategies particularly in tropical regions with a rising prevalence of metabolic disorders.
高血压常与阻塞性睡眠呼吸暂停(OSA)并存。然而,肾素-血管紧张素-醛固酮系统(RAAS)在OSA患者高血压发生中的作用仍不明确,关于这些患者RAAS激活的证据尚无定论。在此,我们旨在评估OSA患者的RAAS概况,并阐明RAAS对这些个体高血压的影响。
在这项观察性研究中,招募了年龄在18岁及以上、来自健康诊所、肥胖(定义为体重指数大于27.5kg/m)且确诊为OSA且符合研究标准的患者。收集人体测量数据,并采集血液样本以检测血浆醛固酮浓度(PAC)和血浆肾素浓度(PRC)。使用治疗强度评分(TIS)评估治疗强度。比较OSA患者、健康对照者和确诊原发性醛固酮增多症患者的RAAS成分。
共招募了204名符合研究标准的患者,其中160名患有高血压。与血压正常的OSA患者相比,高血压OSA患者的PAC更高,PRC无显著差异;与健康对照者相比,高血压OSA患者的PAC和ARR更高,PRC更低。PAC与TIS(β = 0.281,p < 0.001)、收缩压(β = 0.156,p = 0.049)和高血压病程(β = 0.168,p = 0.011)呈正相关,而与高血压诊断呈负相关(β = -0.170,p = 0.024)。
这是东南亚地区第一项评估RAAS对OSA患者高血压严重程度影响的研究。研究结果表明,患有OSA的高血压个体表现出更大的RAAS失调,突出了醛固酮在OSA患者高血压发生及其严重程度中的作用。这也强调了针对性管理策略的必要性,特别是在代谢紊乱患病率不断上升的热带地区。